The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 336,460
- 试验地点
- 3
- 主要终点
- Number of Days of Quetiapine Received
研究概览
简要总结
This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia. Using a randomized controlled trial conducted by the Centers for Medicare and Medicaid Services (CMS) in 2015, this secondary study looks at the effects of potential de-prescribing of antipsychotics by study physicians induced by the letters. The central question is whether the intervention led to better health and quality of life outcomes by encouraging more guideline-concordant care and whether changes in physicians' prescription behavior caused unintended harms.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fully enrolled in Fee-For-Service Medicare Parts A, B, and D
- •For nursing home patients: Residing in a nursing home and has a usable nursing home assessment to measure outcomes
- •For community-dwelling patients: Not residing in a nursing home
- •Has Alzheimer's or dementia related disease diagnosis
- •Attributed to study physician (see study population description)
排除标准
- •Died during 90 day period used to attribute patient to physician
- •For nursing home patients: Short-stay nursing facility patient
结局指标
主要结局
Number of Days of Quetiapine Received
时间窗: 90 days
Days of quetiapine received during the outcome measurement period
次要结局
未报告次要终点
研究者
Adam Sacarny, PhD
Assistant Professor of Health Policy and Management
Columbia University